Loading...
XASXIIQ
Market cap35mUSD
Jan 09, Last price  
0.50AUD
1D
0.00%
1Q
6.25%
Name

INOVIQ Ltd

Chart & Performance

D1W1MN
XASX:IIQ chart
P/E
—
P/S
104.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.32%
Rev. gr., 5y
0.54%
Revenues
535k
+34.39%
296,89677,68605,717,88911,782182,8905,159275,678000044,02862,418520,798535,101468,096276,745398,193535,118
Net income
-7m
L-26.92%
1,370-10,216,274-11,086,1373,161,3123,763,907-1,606,065-1,559,185-10,447,529-10,515,219-758,929-2,984,301-3,270,761-2,604,171-1,783,906-1,717,273-3,253,553-12,367,119-6,514,850-8,969,241-6,554,350
CFO
-4m
L-38.46%
00000000099,375-126,654-78,116-2,378,313-1,965,267-1,570,719-2,536,577-5,260,377-6,061,160-7,024,574-4,322,924
Earnings
Feb 21, 2025

Profile

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
URL
https://www.inoviq.com/
IPO date
Apr 18, 1991
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
535
34.39%
398
43.88%
277
-40.88%
Cost of revenue
7,866
8,593
5,859
Unusual Expense (Income)
NOPBT
(7,331)
(8,195)
(5,582)
NOPBT Margin
Operating Taxes
(1,095)
(2,059)
Tax Rate
NOPAT
(7,331)
(7,100)
(3,523)
Net income
(6,554)
-26.92%
(8,969)
37.67%
(6,515)
-47.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,241
17,221
BB yield
-12.06%
-48.60%
Debt
Debt current
241
362
357
Long-term debt
566
737
1,640
Deferred revenue
Other long-term liabilities
22
7
49
Net debt
(8,426)
(6,713)
(13,397)
Cash flow
Cash from operating activities
(4,323)
(7,025)
(6,061)
CAPEX
(161)
(292)
(412)
Cash from investing activities
(174)
(292)
(412)
Cash from financing activities
5,914
(268)
16,874
FCF
(6,919)
(6,708)
(4,077)
Balance
Cash
9,233
7,813
15,395
Long term investments
Excess cash
9,206
7,793
15,381
Stockholders' equity
19,986
19,615
39,974
Invested Capital
11,206
12,561
13,960
ROIC
ROCE
EV
Common stock shares outstanding
92,424
92,019
90,858
Price
0.56
-34.12%
0.85
117.95%
0.39
-79.26%
Market cap
51,758
-33.83%
78,216
120.73%
35,435
-75.61%
EV
43,332
71,502
22,037
EBITDA
(5,887)
(6,801)
(3,480)
EV/EBITDA
Interest
60
82
Interest/NOPBT